Aug 05, 2020

ODYSSEY LONG TERM hints at reduction in CV events with alirocumab

BARCELONA, Spain — Long-term results indicate that in addition to reducing cholesterol on top of regular statin therapy, treatment with alirocumab also reduced the incidence of CV events. The ODYSSEY LONG TERM trial included 2,341 patients with hypercholesterolemia (≥70 mg/dL at baseline) at high or very high CV risk, including those with heterozygous familial hypercholesterolemia (18%).

Proceed to the page: http://linkis.com/welKq

Similar Articles Added Earlier

Similar Articles Added Today

Most Recent healio.com Articles

  • Efficacy, safety of aspirin for treatment of patients with diabetes, CAD unclear

    BOSTON — The benefits of using aspirin, alone or with a platelet inhibitor, for the treatment of patients with diabetes at high-risk for CVD are still unclear, according to presenters at the Cardiometabolic Health Congress. A debate between Ph. Gabriel Steg, MD, professor of cardiology at...

  • Apixaban superior to warfarin regardless of renal function in patients with AF

    Renal function status had no effect on the superiority of apixaban in efficacy and safety compared with warfarin in patients with atrial fibrillation, according to data published in JAMA Cardiology. In the ARISTOTLE trial, apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) was associated with reduced...

  • Strict glycemic control did not affect survival after CABG

    There was no difference in survival after CABG between patients who underwent a strict glycemic control strategy compared with those who underwent a liberal strategy, according to recent study data. Researchers assessed long-term survival in patients (mean age, 62.7 years; 16% women) randomly...

Latest Links Processed

0/120